Who are CervarixTM (GSK580299)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Human Papillomavirus, HPV vaccine, Recombinant Human Papillomavirus Bivalent Vaccine, Flu Vaccine, HPV-16/18 L1 VLP AS04, HPV-16/18 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cervarixtm-gsk580299.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CervarixTM (GSK580299) — Competitive Intelligence Brief

CervarixTM (GSK580299) (CervarixTM (GSK580299)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prophylactic vaccine. Area: Oncology / Immunology.

phase 3 Prophylactic vaccine Human papillomavirus (HPV) types 16 and 18 Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

CervarixTM (GSK580299) (CervarixTM (GSK580299)) — GlaxoSmithKline. Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 16 and 18, which cause cervical cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CervarixTM (GSK580299) TARGET	CervarixTM (GSK580299)	GlaxoSmithKline	phase 3	Prophylactic vaccine	Human papillomavirus (HPV) types 16 and 18
Human Papillomavirus	Human Papillomavirus	Peking Union Medical College Hospital	marketed	Prophylactic vaccine	Human Papillomavirus capsid protein (L1)
HPV vaccine	HPV vaccine	Fondazione IRCCS Policlinico San Matteo di Pavia	marketed	Prophylactic vaccine	Human papillomavirus (HPV) capsid proteins / L1 antigen
Recombinant Human Papillomavirus Bivalent Vaccine	Recombinant Human Papillomavirus Bivalent Vaccine	National Cancer Institute (NCI)	marketed	Prophylactic vaccine	Human papillomavirus types 16 and 18 (HPV-16, HPV-18)
Flu Vaccine	Flu Vaccine	La Fundacion Favaloro para la Investigacion y la Docencia Medica	marketed	Prophylactic vaccine	Influenza A and B viral hemagglutinin and neuraminidase surface antigens
HPV-16/18 L1 VLP AS04	HPV-16/18 L1 VLP AS04	GlaxoSmithKline	phase 3	Prophylactic vaccine	HPV-16 and HPV-18 L1 capsid protein
HPV-16/18 vaccine	HPV-16/18 vaccine	Shanghai Zerun Biotechnology Co.,Ltd	phase 3	Prophylactic vaccine	HPV-16 and HPV-18 L1 capsid proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prophylactic vaccine class)

GlaxoSmithKline · 5 drugs in this class
La Fundacion Favaloro para la Investigacion y la Docencia Medica · 1 drug in this class
Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Shanghai Zerun Biotechnology Co.,Ltd · 1 drug in this class
Murdoch Childrens Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CervarixTM (GSK580299) — Competitive Intelligence Brief. https://druglandscape.com/ci/cervarixtm-gsk580299. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab